Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Licenses Gene Expression Technology From Genzyme Molecular

Premium

FRAMINGHAM, Mass.--Genzyme Molecular Oncology here and Bayer have inked an agreement that will allow Bayer the use of Genzyme Molecular Oncology's patented Serial Analysis of Gene Expression (SAGE) technology.

Bayer will utilize SAGE to identify genes that may have importance in drug development. Financial terms of the agreement were not disclosed.

SAGE is a patented method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time and can be used in a variety of applications to identify disease-related genes, analyze the effect of drugs on tissues, and provide insight into disease pathways. Because SAGE is a high-throughput method, it may be used to detect differences in rarely expressed but highly significant genes, according to Genzyme.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.